Tipifarnib in Treating Patients With Recurrent or Progressive Malignant Glioma
Completed · Phase 1/Phase 2
Conditions studied: Brain and Central Nervous System Tumors
In brief
RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent or progressive malignant glioma.
Key facts
- Study ID
- NCT00005859
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 136
- Starts
- 2000-05-16
- Expected to finish
- 2006-08-01
- Last updated by the study team
- 2018-06-26
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States
- UCSF Comprehensive Cancer Center — San Francisco, California, United States
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute — Boston, Massachusetts, United States
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
- Memorial Sloan-Kettering Cancer Center — New York, New York, United States
- Hillman Cancer Center at University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
- Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas — Dallas, Texas, United States
- University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
- University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
- University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.